The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Percutaneous Peripheral Nerve Stimulation Systems for Pain Receive FDA Clearance

Aug. 16, 2018 - SPR Therapeutics' SPRINT peripheral nerve stimulation systems have received FDA clearance for use in pain management, the company announced. The company has single-lead and dual-lead percutaneous devices that are charged by a wearable pulse generator. The company said the systems are indicated for use for up to 60 days in the back and/or extremities for chronic and acute pain. (Medscape)

Neuromodulation Company Addressing Vision Loss Announces $5 Million Private Placement

Aug. 16, 2018 - Second Sight Medical announced a private placement in which it is selling about 3.2 million shares of common stock for $1.55 a share to entities owned by its board chair Gregg Williams. The net proceeds of about $5 million will will help support continued development, studies, and evidence-collection for its visual prosthesis systems and devices. (Mass Device)

Laboratory Project Would Demonstrate a Nervous System Implant that Combines Electrical, Chemical, Thermal, and Optical Functionalities

July 31, 2018 - A five-year, 1.5 million Euro project to develop neuroprosthetic implants for the brain with electrical, chemical, thermal and optical modes has been approved by the European Research Council at the Dresden University of Technology. The project, known as Integrated Implant Technology for Multimodal Brain Interfaces (IntegraBrain), will begin with demonstration in rats of a cortical interface to control focal seizures, and a peripheral nerve interface to control visceral function. (TU Dresden)

Company Announces a 4-Year, $1 Million Preclinical Research Collaboration on Non-Invasive Vagus Nerve Stimulation and Neuroinflammation  

Aug. 9, 2018 - The company electroCore, Inc. announced it has entered a preclinical research partnership with Massachusetts General Hospital to study the mechanisms of inflammatory processes associated with central nervous system conditions, such as pain, trauma, and neurodegredation. The company will provide up to $1 million over four years for the studies, including two recently begun studies on non-invasive vagus nerve stimulation (VNS). One study focuses on persistent neuroinflammation and the neurological outcomes after concussive traumatic brain injury; the other, on effects on microglia cells and their association with the development and progression of Alzheimer’s disease. Previously, the company supported preclinical investigations at the same institution regarding neuroinflammatory mechanisms associated with migraine and their modulation by non-invasive VNS. (Globe Newswire)

Manitoba Clinic Seeks Participants for Study of Repetitive Transcranial Magnetic Stimulation in Depression

Aug. 8, 2018 - A Manitoba, Canada clinic will participate in a clinical trial of repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant depression. The article states that although the provinces of Quebec and Saskatchewan cover rTMS for mood disorders, Manitoba Health decided against covering it in 2016. The clinic opened in 2012 and has a six-month waiting list. Its management has been fundraising and applying for grants to help cover costs for patients who cannot afford to pay for the treatment. (CBC)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM